Clemastine alleviates cognitive dysfunction after SAH by targeting neuronal CNTN1 to regulate the ADA-adenosine...

Area of Science:

• Neuroscience
• Molecular Biology
• Pathology

Background:

• Demyelination after subarachnoid hemorrhage (SAH) contributes to cognitive impairment.
• The molecular mechanisms driving SAH-related demyelination are not fully understood.
• Contactin-1 (CNTN1) levels are decreased in SAH patients' cerebrospinal fluid and correlate with cognitive scores.

Purpose of the Study:

• To investigate the cellular source of CNTN1 downregulation in the SAH brain.
• To elucidate the molecular pathways linking CNTN1 to SAH-induced demyelination and cognitive dysfunction.
• To identify potential therapeutic targets for SAH-related cognitive impairment.

Main Methods:

• Single-cell RNA sequencing to identify cell-type-specific gene expression changes.
• Adeno-associated virus (AAV) mediated knockdown and overexpression of Cntn1 in mouse models.
• Transcriptome sequencing to analyze gene expression alterations.
• Pharmacological inhibition of ADA and administration of clemastine.

Main Results:

• Cntn1 was downregulated specifically in neurons, not oligodendrocytes, following SAH.
• Neuronal Cntn1 knockdown exacerbated SAH-induced cognitive deficits and demyelination.
• CNTN1 knockdown led to decreased expression of Ada, Plp1, and Mbp, suggesting a CNTN1-ADA-ADORA2B signaling axis.
• Cntn1 overexpression in neurons improved cognitive function in SAH mice, an effect blocked by ADA inhibition.
• Clemastine treatment mitigated SAH-induced cognitive impairment and demyelination.

Conclusions:

• Neuronal CNTN1 is a critical regulator of demyelination and cognitive function after SAH.
• Downregulation of CNTN1 exacerbates demyelination via the ADA pathway.
• Clemastine represents a potential therapeutic strategy for cognitive deficits in SAH patients.